MiMedx Group, Inc (MDXG) is a publicly traded Healthcare sector company. As of May 21, 2026, MDXG trades at $3.71 with a market cap of $534.72M and a P/E ratio of 11.35. MDXG moved +4.40% today. Year to date, MDXG is -40.13%; over the trailing twelve months it is -47.14%. Its 52-week range spans $3.03 to $10.14. Analyst consensus is strong buy with an average price target of $6.20. Rallies surfaces MDXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MiMedx Launches G4Derm Plus Nationwide, Secures Premier and Vizient GPO Agreements: MiMedx launched G4Derm Plus, a 510(k)-cleared acellular flowable ECM using self-assembling peptides, with initial sales delivered nationwide. It secured Premier and Vizient GPO agreements for national distribution, expanding its surgical wound-care portfolio.
| Metric | Value |
|---|---|
| Price | $3.71 |
| Market Cap | $534.72M |
| P/E Ratio | 11.35 |
| EPS | $0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.14 |
| 52-Week Low | $3.03 |
| Volume | 300 |
| Avg Volume | 0 |
| Revenue (TTM) | $418.63M |
| Net Income | $48.58M |
| Gross Margin | 82.56% |
5 analysts cover MDXG: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.20.